Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin plus atezolizumab versus atezolizumab maintenance in extensive-stage small-cell lung cancer
2021-001930-20Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Lurbinectedin + atezolizumab maintenance with Atezolizumab maintenance (2 arms). Primary endpoints: IRF-assessed progression-free survival and Overall survival. Started Dec 2021; status: active.
02
Drugs
lurbinectedinatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-001930-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001930-20.